Abiopharma

New Form 8-K - BECTON DICKINSON & CO Filed: 2025-08-07 AccNo: 0000010795-25-000069 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

New Form 6-K/A - Prenetics Global Ltd Filed: 2025-08-07 AccNo: 0001628280-25-038549 Size: 141 KB

Zimmer Biomet Holdings, Inc. Notification

New Form 10-Q - Aveanna Healthcare Holdings, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104528 Size: 11 MB

New Form 8-K - ZIMMER BIOMET HOLDINGS, INC. Filed: 2025-08-07 AccNo: 0000950170-25-104527 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Aveanna Healthcare Holdings, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104525 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Aveanna Healthcare Holdings Announces Second Quarter Financial Results and Revised 2025 Outlook

BD Reports Third Quarter Fiscal 2025 Financial Results

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

New Form 8-K - Elanco Animal Health Inc Filed: 2025-08-07 AccNo: 0001739104-25-000052 Size: 749 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Elanco Animal Health Inc. - Elanco Animal Health Reports Second Quarter 2025 Results

Elanco Animal Health Reports Second Quarter 2025 Results

Lillys oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity

New Form 10-Q - Zai Lab Ltd Filed: 2025-08-07 AccNo: 0001628280-25-038548 Size: 6 MB